Atenolol
From Pharmacopedia
More actions
Atenolol
Tenormin
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Hypertension (FDA, though displaced from first-line by JNC8 and contemporary guidelines)0, Angina pectoris (FDA)0, Post-myocardial-infarction secondary prevention (FDA)0, Atrial fibrillation rate control (off-label)0, Supraventricular tachycardia (off-label)0
Pharmacy
Starting dose
25-50 mg PO once daily; titrate to 100 mg/day
Preparations
Tablets 25, 50, 100 mg
US FDA Max
100-200 mg/day depending on indication
Pharmacology
Routes
Oral
Onset
BP effect within hours; full effect over 1-2 weeks
Duration
24 hours (once-daily dosing supported by long elimination)
Half-life
6-9 hours (substantially longer in renal impairment due to renal elimination)[1]
Bioavailability
~50% (oral)[1]
Pregnancy
Documented fetal growth restriction with chronic exposure; avoid in pregnancy if alternative β-blockers are appropriate. The β-blocker most consistently associated with intrauterine growth concerns[1]
Legal status
Rx-only in US
Purported mechanism
Selective β1-adrenergic receptor antagonist with minimal β2 activity at therapeutic doses, giving lower bronchoconstriction risk than non-selective β-blockers. Hydrophilic (unlike lipophilic propranolol and metoprolol), so it has very limited CNS penetration, giving much less CNS adverse-effect burden (depression, fatigue, vivid dreams) but correspondingly less migraine prophylactic efficacy compared to lipophilic β-blockers. Renally eliminated, so accumulates in renal impairment and requires dose adjustment by creatinine clearance.0 Contemporary hypertension guidelines (JNC8 and onward) have moved atenolol away from first-line antihypertensive use based on trial data showing inferior cardiovascular outcomes versus other antihypertensive classes, particularly in older patients[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Tenormin (atenolol), AstraZeneca/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018240s031lbl.pdf